If your body mass index is 30 or greater, or if you have a BMI of 27 with a weight-related medical condition like hypertension, type 2 diabetes, or hyperlipidemia, the semaglutide weight loss program could be suitable for you
Based on data from the STRIDE clinical trial, Novo Nordisk submitted a label extension application for Ozempic to the EMA and the FDA
To manage this shift, we recommend a few supportive strategies: Hydration is Key: Drink plenty of water and consider adding electrolytes
Patient Selection: With most cardiovascular patients having BMI 27 kg/m, this represents a large eligible population who may derive cardiovascular benefit from semaglutide, independent of achieving substantial weight reduction
Future Research Directions in AOM Timing As newer anti-obesity medications enter clinical practice, understanding their potential in early intervention for GLP-1 non-responders becomes increasingly crucial